Literature DB >> 17683379

Paraneoplastic pemphigus.

Xuejun Zhu1, Bingxin Zhang.   

Abstract

Paraneoplastic pemphigus (PNP) is a life-threatening autoimmune blistering skin disease. Clinically, it is characterized by severe mucosal erosions and various cutaneous lesions associated with lymphoproliferative neoplasmas. Suprabasal acantholysis and clefts with scattered necrotic keratinocytes are the unique histopathological features. PNP patient sera recognize multiple antigens, which have been identified as the plakin protein family that includes desmoplakin, bullous pemphigoid antigen I (BPAG1), envoplakin and periplakin, and desmogleins 1 and 3. Castleman's tumor, non-Hodgkin's lymphoma, thymoma, follicular dendritic cell sarcoma and chronic lymphocytic leukemia are the commonly associated neoplasmas in PNP. We have also demonstrated that the autoantibodies reacting to epidermal proteins are directly produced by the cells in the associated tumors. Bronchiolitis obliterans is frequently found in PNP and may cause respiratory failure and death. In our experience, the early detection and removal of the tumor and i.v. administration of immunoglobulin are critical for the treatment of PNP.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17683379     DOI: 10.1111/j.1346-8138.2007.00322.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  25 in total

Review 1.  Paraneoplastic pemphigus in a burn intensive care unit: case report and review of the literature.

Authors:  Awori J Hayanga; Timothy M Lee; Christopher J Pannucci; Brian S Knipp; Stephen H Olsen; Stewart C Wang; Lena M Napolitano
Journal:  J Burn Care Res       Date:  2010 Sep-Oct       Impact factor: 1.845

Review 2.  Chronic lymphocytic leukemia and autoimmunity: a systematic review.

Authors:  Kate Hodgson; Gerardo Ferrer; Emili Montserrat; Carol Moreno
Journal:  Haematologica       Date:  2011-01-17       Impact factor: 9.941

3.  The protease inhibitor alpha-2-macroglobulin-like-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human.

Authors:  Isabelle Schepens; Fabienne Jaunin; Nadja Begre; Ursula Läderach; Katrin Marcus; Takashi Hashimoto; Bertrand Favre; Luca Borradori
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

4.  A critical role of surgery in the treatment for paraneoplastic pemphigus caused by localized Castleman's disease.

Authors:  Yujiang Fang; Lei Zhao; Feng Yan; Xijun Cui; Yue Xia; Alicia Duren
Journal:  Med Oncol       Date:  2009-09-11       Impact factor: 3.064

5.  A Case of Paraneoplastic Pemphigus as a Preceding Manifestation of Underlying Follicular Lymphoma Treated with R-CHOP.

Authors:  Minsu Kim; Ji Yun Lee; Soo-Chan Kim; Jung-Im Na
Journal:  Ann Dermatol       Date:  2021-05-04       Impact factor: 1.444

Review 6.  Refractory pemphigus foliaceus and Behçet's disease successfully treated with tocilizumab.

Authors:  Francesco Caso; Luca Iaccarino; Silvano Bettio; Francesca Ometto; Luisa Costa; Leonardo Punzi; Andrea Doria
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

7.  Pemphigus with thymoma improved by thymectomy: report of a case.

Authors:  Mitsuteru Yoshida; Takanori Miyoshi; Syoji Sakiyama; Kazuya Kondo; Akira Tangoku
Journal:  Surg Today       Date:  2012-08-02       Impact factor: 2.549

8.  Paraneoplastic syndromes in thymoma: an immunological perspective.

Authors:  Robert P Nelson; Robert M Pascuzzi
Journal:  Curr Treat Options Oncol       Date:  2009-02-06

9.  Features and Risk Factors for Paraneoplastic Autoimmune Multiorgan Syndrome in 145 Chinese Patients.

Authors:  Mingyue Wang; Furong Li; Xintong Wang; Xue Wang; Rui Wang; Yinmo Yang; Jian Li; Shijie Zhang; Weiming Huang; Yujun Dong; Xiangdong Mu; Ting Li; Kaiwen Ni; Xixue Chen; Xuejun Zhu
Journal:  Acta Derm Venereol       Date:  2020-11-04       Impact factor: 3.875

Review 10.  Molecular diagnosis in autoimmune skin blistering conditions.

Authors:  J V Otten; T Hashimoto; M Hertl; A S Payne; C Sitaru
Journal:  Curr Mol Med       Date:  2014-01       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.